Users Coming Off Weight-Loss Jabs Gain Back Weight Four Times Faster Compared to Dieters

New research reveals that individuals who stop using new GLP-1 drugs like Wegovy and Mounjaro may regain lost weight much more quickly than those who stop traditional lifestyle regimens.

Research printed in a major medical journal shows that while obese people frequently drop substantial amounts of their total mass while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.

"People buying such medications need to be cognizant of the potential of quick rebound weight gain when the therapy ends," warns lead investigator Dr. Susan Jebb.

That rate of recovery suggests a reversion to starting mass in about one and a half years.

Weighing Therapies

The analysis, which looked at 37 of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with conventional dieting.

Researchers point out that individuals who shed pounds through diet and exercise generally see a less rapid weight regain—perhaps 0.1 kg a month—once they finish.

The Reason for the Quick Rebound

Experts believe the mode of action of the drugs accounts for the accelerated weight return.

GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.

"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its actions," said Dr. Adam Collins, a nutrition expert.

"Stopping of this hormone supplement means hunger is unsuppressed, making overeating much more probable."

A Chronic Condition?

Health authorities suggest the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.

Many experts contend that, considering the high risk of relapse, the therapy might need to be long-term.

This opinion is supported by pharmaceutical companies, who say that the results "underscore the long-term character of obesity," comparing it to managing conditions like high blood pressure.

User Experiences

People who have discontinued the jabs report a powerful resurgence of hunger.

"It was like something activating and you become extremely hungry," recalled a patient.

This difficulty is worsened if individuals have not adopted lasting dietary or behavioural changes during treatment.

Widespread Interest

Recent estimates suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with interest remaining high.

• Adoption is more common among females compared to men.
• The middle-aged age group shows the greatest level of interest.
• A large proportion access the drugs through private prescriptions rather than the NHS.

In conclusion, clinicians emphasize that while the jabs are effective agents for weight loss, they are not a permanent fix and long-term success likely depends on integrated behavioural support.